Purpose:
To evaluate the prevalence and risk factors for development of paravascular inner retinal defects (PIRD) using en face OCT.
Methods:
Retrospective cross-sectional study. En face and cross-sectional OCT images were reviewed (9x9 mm or 12x12 mm). PIRD were classified as either grade 1 (i.e. paravascular inner retinal cysts) when the lesion was confined within the nerve fiber layer without any communication to the vitreous cavity or grade 2 (i.e. paravascular lamellar hole) when the defects communicated to the vitreous. PIRD grading was correlated with presence of high myopia, stage of posterior vitreous detachment (PVD), and presence of epiretinal membrane (ERM) and retinoschisis.
Results:
Of 1074 patients (2148 eyes), PIRD were detected in 261 eyes with a prevalence of 261 per 2148 eyes (12.2%) and 176 per 1074 patients (16.4%). A total of 116 eyes (44.4%) displayed grade 2 PIRD while 145 eyes (55.6%) were grade 1. In the multivariate logistic regression model, the presence of partial/complete PVD, retinoschisis and ERM were significantly correlated with PIRD (OR=2.78 [1.7-4.4], p<0.001; OR=2.93 [1.7-5], p< 0.001 and OR=25.9 [2.8-242.5], p<0.001 respectively). The presence of partial/complete PVD and ERM were also significantly associated with grade 2 PIRD versus grade 1 PIRD (p=0.03 and p< 0.001).
Conclusions:
Our results indicate that wide field en face OCT facilitates the identification of PIRD over a large area of retina with a single capture. The presence of PIRD was significantly associated with PVD, ERM and retinoschisis, confirming the role of vitreoretinal traction in the pathogenesis of PIRD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.